Letermovir
- TRADE NAME: Prevymis (Merck Sharpe & Dohme)
- INDICATIONS: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.
- CLASS: Antiviral, Viral terminase complex inhibitor
- HALF-LIFE: 12 hours
FDA APPROVAL DATE: 11/08/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfentanil, Amiodarone, Atorvastatin, Cyclosporine, Dihydroergotamine, Ergotamine, Fentanyl, Fluvastatin, Glyburide, Lovastatin, Midazolam, Omeprazole, Pantoprazole, Phenytoin, Pimozide, Pitavastatin, Pravastatin, Quinidine, Repaglinide, Rifampin, Rosiglitazone, Rosuvastatin, Simvastatin, Sirolimus, Tacrolimus, Voriconazole, Warfarin
PREGNANCY CATEGORY: N/A
No adequate human data available
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric